EUVIMEDEUVIMED entdecken
Multizentrische Studie

Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns

Simona Casalino, Enza Scarlato, Marina Crespo Cruz, Christoph Gerdes, Anna Sordo, Alberto Quinzii, Camilla Zecchetto, Luisa Messineo, Ester Tasselli, Lucia Mendo, Anna Saborowski, John Bridgewater und 2 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.117036 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Simona Casalino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy; Centro Ricerche Cliniche, Verona, Italy. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro, NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsCholangiocarcinomaDrug Resistance, NeoplasmProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2AdultAgedFemaleHumansMaleMiddle AgedMutationPyrazinesPyrazolesPyrimidinesPyrrolesRetrospective Studies

Stichwörter der Autor:innen

Drug resistanceFGFR2FutibatinibIntrahepatic cholangiocarcinomaPolyclonal mutationsPrecision medicineTargeted therapy

Substanzen

FGFR2 protein, humanfutibatinibProtein Kinase InhibitorsPyrazinesPyrazolesPyrimidinesPyrrolesReceptor, Fibroblast Growth Factor, Type 2

Autor:innen und Institutionen

  • Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy; Centro Ricerche Cliniche, Verona, Italy.
  • Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy.
  • Department of Oncology, University College Hospital, London, UK.
  • Department of Gastroenterology, Hepatology , Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Centro Ricerche Cliniche, Verona, Italy.
  • Department of Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza, Italy.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • NextGenerationEU

Zitieren

APA

Casalino, S., Scarlato, E., Cruz, M. C., Gerdes, C., Sordo, A., Quinzii, A., Zecchetto, C., Messineo, L., Tasselli, E., Mendo, L., Saborowski, A., Bridgewater, J., Vogel, A., & Melisi, D. (2026). Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117036

Vancouver

Casalino S, Scarlato E, Cruz MC, Gerdes C, Sordo A, Quinzii A, et al. Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117036

BibTeX
@article{Casalino2026,
  author = {Casalino, Simona and Scarlato, Enza and Cruz, Marina Crespo and Gerdes, Christoph and Sordo, Anna and Quinzii, Alberto and Zecchetto, Camilla and Messineo, Luisa and Tasselli, Ester and Mendo, Lucia and Saborowski, Anna and Bridgewater, John and Vogel, Arndt and Melisi, Davide},
  title = {Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.117036}
}
Kostenlos starten →